Neurocrine gets rights to Bial-Portela's PD drug

Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) exclusive, North American rights to Parkinson's disease drug Ongentys opicapone (ONO-2370).

Bial-Portela will receive $30 million up front and is eligible for $115 million in milestones, plus 37% of net sales in exchange for manufacturing and supplying the drug...